Cancer Therapy–Related Cardiac Dysfunction in Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy

• Published in: Journal of the American Heart Association Vol. 12; no. 19; p. e030447
• Main Authors: Chen, Dong‐Yi, Lee, Cheng‐Hung, Tsai, Ming‐Lung, Hsieh, Ming‐Jer, Chuang, Cheng‐Keng, Pang, See‐Tong, Chen, Shao‐Wei, Tseng, Chi‐Nan, Chang, Shang‐Hung, Chu, Pao‐Hsien, Hsieh, I‐Chang, Wu, Victor Chien‐Chia, Huang, Wen‐Kuan
• Format: Journal Article
• Language: English
• Published: England John Wiley and Sons Inc 03.10.2023; Wiley
• Subjects: Androgen Antagonists - adverse effects; androgen deprivation therapy; Androgens; cardiovascular toxicity; Gonadotropin-Releasing Hormone; Heart Diseases - chemically induced; Humans; Male; Orchiectomy - adverse effects; Original Research; prostate cancer; Prostatic Neoplasms - drug therapy; Prostatic Neoplasms - epidemiology; Stroke Volume; Ventricular Function, Left; androgen deprivation therapy; cardiovascular toxicity; prostate cancer
• ISSN: 2047-9980; 2047-9980
• DOI: 10.1161/JAHA.123.030447

Background The risk of cardiac dysfunction for patients with prostate cancer undergoing androgen deprivation therapy (ADT) in the real-world setting remains unclear. Methods and Results A total of 1120 patients with prostate cancer and a baseline echocardiography scan were identified from Chang Gung Research Database between January 1, 2001 and December 31, 2019. Patients were treated with gonadotropin-releasing hormone agonist therapy, gonadotropin-releasing hormone antagonist therapy, or bilateral orchiectomy. Changes in left ventricular ejection fraction (LVEF) were further assessed in 421 patients using repeated measurements of LVEF before and during ADT treatment. The incidence of cancer therapy-related cardiac dysfunction (CT-RCD) was evaluated and defined as a ≥10% absolute decline in LVEF from baseline to a value of <53%. Among 421 patients undergoing ADT, LVEF declined from 66.3±11.3% to 62.5±13.6% (95% CI of mean difference: -5.0% to -2.7%) after a mean follow-up period of 1.6±0.8 years. CT-RCD occurred in 58 patients (13.7%) with a nadir LVEF of 40.3±9.1% after ADT. Lower baseline LVEF was significantly associated with CT-RCD (odds ratio, 1.07 [95% CI, 1.04-1.10]). The area under the curve of baseline LVEF for discriminating CT-RCD was 75.6%, with the corresponding optimal cutoff value of 64.5% (sensitivity, 79.3%; specificity, 67.2%). Conclusions ADT with gonadotropin-releasing hormone agonist therapy, gonadotropin-releasing hormone antagonist therapy, and bilateral orchiectomy were associated with an increased risk of CT-RCD in patients with prostate cancer. In addition, lower baseline LVEF was a significant predictor of CT-RCD in patients with prostate cancer undergoing treatment with ADT.